drugset / Trial / NCT04640233
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
Phase 2/3
Unknown
1600 enrolled
Dr. Reddy's Laboratories Limited
CRO: JSS Medical Research India Pvt. Ltd. · collabGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · collabRussian Direct Investment Fund · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.
Timeline
- Start
- 2020-11-30
- Primary completion
- 2021-08
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gam-COVID-Vac | Vaccine | 0.5 ml | Intramuscular |
Indications
No indication recorded.